94 results on '"Rukazenkov, Y."'
Search Results
2. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
3. Osimertinib vs. Vergleichs-EGFR-TKI als Erstlinientherapie bei EGFRm fortgeschrittenem NSCLC (FLAURA): Finale Overall Survival Analyse
4. Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
5. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
6. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
7. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
8. Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
9. Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
10. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
11. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
12. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
13. 128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
14. P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
15. PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
16. Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA
17. CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
18. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
19. LBA16 - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
20. LBA17 - Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
21. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
22. LBA5_PR - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
23. LBA85 - Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
24. Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
25. LBA8 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
26. 489O - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
27. LBA50 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
28. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
29. 35P_PR - CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
30. LBA5 - CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
31. 413O - Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA
32. LBA2_PR - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
33. Azd9291, a Third Generation EGFR Inhibitor, Versus Gefitinib or Erlotinib in Treatment-Naïve Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring an Egfr-Tki-Sensitising Mutation (EGFRM): a Randomised, Phase Iii Study (FLAURA)
34. Prognostic Role of Luminal Subtype in Metastatic Breast Cancer Patients Treated with Fulvestrant in the Confirm Trial
35. Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial
36. 1201O - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
37. Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
38. Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
39. 9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS
40. 9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study
41. Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS)
42. 31P - Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial
43. 30P - Prognostic Role of Luminal Subtype in Metastatic Breast Cancer Patients Treated with Fulvestrant in the Confirm Trial
44. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
45. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
46. 514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2.
47. 122P Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
48. Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg.
49. Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.
50. Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.